NCT02608528终止不适用
Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Number of inflammatory changes within the tumor
研究概览
简要总结
Evaluation of FDG PET/CT to image immunotherapy response in adult thoracic cancer.
Compare pre- and post-treatment primary tumor uptake for FDG-PET/CT and correlate with clinical markers of response. PET/CT tumor metabolic response will also be correlated will to progression-free survival and overall survival.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients, at least 18 years of age
- •Histologically confirmed non-small cell lung cancer or malignancy pleural mesothelioma with at least one site of disease > 1 cm by at least one type of standard imaging (e.g.
- •CT, chest x-ray, MRI)
- •Recommended to start anti-PD1/PDL1 therapy.
- •Obtaining pre-PD1/PDL1 therapy clinical re-staging [18F]FDG-PET/CT scan at the Hospital of the University of Pennsylvania.
- •Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.
- •Participants must be willing and able to comply with scheduled visits and imaging procedures in the opinion of the investigator or treating physician.
- •Exclusion Criteria
- •Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study. Female participants of child-bearing potential will have a urine pregnancy test at the time of the screening visit.
- •Patients with only a single site of primary non-small cell lung cancer or malignancy pleural mesothelioma who have undergone or are recommended to undergo radiation therapy to that site will not be eligible, the inclusion of patients who may be undergoing radiation therapy to ancillary disease sites may be allowed to enter the study at the discretion of the PI if it is not felt to affect the ability to capture [18F]FDG information for at least one primary site of disease.
- •Patients who have undergone cancer surgery removing a significant portion of active disease, in the opinion of an investigator, within 2 months prior to study enrollment will be excluded.
- •Patients who have received prior immunotherapy.
- •Patients with an active auto-immune disease (ie. Multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, vasculitis).
- •Inability to tolerate imaging procedures in the opinion of the investigator or treating physician
- •Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.
- •Unwilling or unable to provide informed consent
排除标准
- 未提供
结局指标
主要结局
Number of inflammatory changes within the tumor
时间窗: 2 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
The Role of 18F-FDG-PET/CT Scan in Lung Cancer PatientsLung CancerNCT04395651Assiut University30
已完成
不适用
The Role of FDG-PET/CT Imaging in the Management of Patients With Thromboembolic Disorders (The PETVET Study)Venous Thromboembolic DiseaseNCT01466426Odense University Hospital40
尚未招募
不适用
Added Value of PET/CT in Lung CancerLung CancerNCT06494800Sohag University30
已完成
不适用
Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of MalignancyNeoplasmsNCT00725387Stanford University214
Unknown
4 期
Evaluation of PET CT in the Management of Patients With Crohn's Disease.Crohn's DiseaseNCT00731809Rabin Medical Center50